Mezzion Pharma Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mezzion Pharma Co., Ltd. - overview
Established
2002
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Based in South Korea, Mezzion Pharma Co. , Ltd. focuses on developing innovative pharmaceutical products, particularly Udenafil, which targets rare medical conditions to enhance patient quality of life. Mezzion Pharma Co.
, Ltd. is engaged in pharmaceutical product development, specifically specializing in Udenafil for rare diseases. Founded in 2002 in Seoul, South Korea, the company has undergone strategic changes to focus on innovative drug solutions. Dong Park currently leads the company.
Mezzion has secured a total of USD 40. 00 mn through 2 funding deals, the most recent being a PIPE investment from BRV Capital Management. The total amount raised to date stands at USD 40. 00 mn.
Mezzion specializes in developing innovative pharmaceutical products, focusing mainly on the new drug candidate Udenafil aimed at various medical conditions, including Fontan-Associated Liver Disease (FALD). Udenafil has shown safety and efficacy in clinical trials, with the company targeting healthcare providers, patients with specific conditions, and rare disease management institutions globally, particularly in the U. S. , Europe, and other international markets.
In the most recent fiscal year of 2024, Mezzion reported a revenue of USD 6,318. 15 mn, while its EBITDA for the same year was USD -10,093. 94 mn. The company generates revenue through licensing and commercialization of its pharmaceutical products, including partnerships for co-development and marketing rights, and aims to provide access to Udenafil for specific patient demographics.
Mezzion Pharma Co. , Ltd. plans to launch additional products targeting rare diseases in the upcoming years. The company is also focused on expanding its presence in key markets, specifically targeting the U.
S. and European regions by 2025. Recent funding from KB Asset Management will support these initiatives, although financial terms were not disclosed. This strategic investment is expected to enhance Mezzion's capabilities in drug development and market entry.
In June 2025, Mezzion Pharma Co. , Ltd. raised approximately USD 20 million in venture funding co-led by Midas Asset Management and KDB Capital. The company will use the June 2025 funding to support the Phase 3 FUEL-2 trial of udenafil for patients with Fontan circulation around the world.
Current Investors
KB Asset Management, BRV Capital Management, KDB Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.mezzion.co.kr
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Mezzion Pharma Co., Ltd. - timeline of key events
Mezzion Pharma Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 8,592,282,536 | 4,402,241,066 | 4,454,554,854 | 14,926,335,581 | 8,751,241,483 | 5,585,879,988 | 19,087,500,191 | 18,930,987,559 | 28,634,181,276 | 26,653,873,354 | 30,726,176,390 | - | - | - |
| % Revenue Growth (YoY) | - | (48.8%) | 1.2% | 235.1% | (41.4%) | (36.2%) | 241.7% | (0.8%) | 51.3% | (6.9%) | 15.3% | - | - | - |
| EBITDA (USD) | 1,729,052,655 | (2,472,531,410) | (4,916,395,324) | (2,389,654,648) | (6,805,195,355) | (16,783,862,970) | (21,698,394,196) | (23,327,365,227) | (6,098,383,117) | (15,211,505,309) | (23,329,621,802) | - | - | - |
| Operating Income (USD) | 1,680,497,655 | (2,472,531,410) | (4,916,395,324) | (2,733,007,648) | (7,220,098,355) | (16,846,231,970) | (21,925,916,196) | (24,658,887,227) | (7,530,525,117) | (16,797,556,309) | (23,331,280,109) | - | - | - |
| Operating Margin | 19.6% | (56.2%) | (110.4%) | (18.3%) | (82.5%) | (301.6%) | (114.9%) | (130.3%) | (26.3%) | (63.0%) | (75.9%) | - | - | - |
| % EBITDA Margin | 20.1% | (56.2%) | (110.4%) | (16.0%) | (77.8%) | (300.5%) | (113.7%) | (123.2%) | (21.3%) | (57.1%) | (75.9%) | - | - | - |
| NET Income (USD) | 2,384,645,812 | (830,751,908) | (2,567,820,636) | 4,222,556,930 | (12,984,660,752) | (14,881,751,606) | 18,876,287,918 | (23,251,204,215) | (13,829,312,496) | (13,602,674,400) | (36,297,830,143) | - | - | - |
| % Net Margin | 27.8% | (18.9%) | (57.6%) | 28.3% | (148.4%) | (266.4%) | 98.9% | (122.8%) | (48.3%) | (51.0%) | (118.1%) | - | - | - |
Mezzion Pharma Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Mezzion Pharma Co., Ltd. | - | ||||||||
| PIPE | Completed | Mezzion Pharma Co., Ltd. | - | ||||||||
| PIPE | Completed | Mezzion Pharma Co., Ltd. | - |
Displaying 1 - 3 of 3
Mezzion Pharma Co., Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.